InvestorsHub Logo
Followers 0
Posts 139
Boards Moderated 0
Alias Born 06/08/2010

Re: None

Friday, 02/03/2012 1:09:55 PM

Friday, February 03, 2012 1:09:55 PM

Post# of 167
"Alkermes earned $0.3 million in royalty revenues from type II diabetes treatment Bydureon" - Positive sign for Amylon EU revenues so far. http://www.zacks.com/stock/news/69054/Revenues+Skyrocket+at+Merged+Alkermes